Thus, nanobody–drug conjugates for cancer therapy should be devised to take the EPR effect. 11A4-ABD-maleimide-auristatin F that can bind to albumin is an interesting example [43]. Nanobody-loaded nanoparticles with payloads will be developed in this field. Anti-receptor nanobodies can act ...
cancerous cell surface acts as a marker that differentiates the normal cell and facilitates the recognition of cancerous cells. An emerging anticancer treatment, Antibody–Drug Conjugates (ADCs), utilises this unique feature to kill cancerous cells. ADCs consist of an antibody linked with a ...
SORT1;ADC;MMAE;DXd;internalization;breast cancer 1. Introduction Developing antibody–drug conjugates (ADCs) through coupling cytotoxic agents to antibodies has often proven to be a better therapeutic option for treating cancer compared to using antibodies alone, and more than 10 ADC agents have alrea...
cancer has involved chemotherapy in combination with monoclonal antibodies that target the HER2 receptor, notably trastuzumab and pertuzumab. However, resistance to these drugs has been ubiquitous, presenting challenges in the management of the disease. Antibody–drug conjugates (ADCs) represent a ...